{"id":"NCT01289119","sponsor":"Takeda","briefTitle":"Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes","officialTitle":"An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Determine the Efficacy and Safety of SYR-322 When Used in Subjects With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2011-12","completion":"2011-12","firstPosted":"2011-02-03","resultsPosted":"2013-03-22","lastUpdate":"2013-03-22"},"enrollment":506,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Alogliptin","otherNames":["SYR-322"]},{"type":"DRUG","name":"Placebo to alogliptin","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":["Fortamet","Glucophage","Glumetza"]},{"type":"DRUG","name":"Pioglitazone","otherNames":["Actos"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Alogliptin Monotherapy","type":"EXPERIMENTAL"},{"label":"Metformin","type":"OTHER"},{"label":"Metformin + Alogliptin Add-on Therapy","type":"EXPERIMENTAL"},{"label":"Pioglitazone","type":"OTHER"},{"label":"Pioglitazone + Alogliptin Add-on Therapy","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to determine the efficacy of alogliptin compared to placebo when given alone or as add-on therapy to metformin or add-on to pioglitazone (with or without metformin).","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Hemoglobin (HbA1c)","timeFrame":"Baseline and Week 16.","effectByArm":[{"arm":"Placebo","deltaMin":-0.42,"sd":0.074},{"arm":"Alogliptin Monotherapy","deltaMin":-0.99,"sd":0.074},{"arm":"Metformin","deltaMin":-0.22,"sd":0.065},{"arm":"Metformin + Alogliptin Add-on Therapy","deltaMin":-0.91,"sd":0.065},{"arm":"Pioglitazone","deltaMin":-0.25,"sd":0.097},{"arm":"Pioglitazone + Alogliptin Add-on Therapy","deltaMin":-0.76,"sd":0.101}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG002 vs OG003","p":"<0.001"},{"comp":"OG004 vs OG005","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":21,"countries":["China","Hong Kong","Taiwan"]},"refs":{"pmids":["38837240"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":92},"commonTop":["Hyperlipidaemia","Upper respiratory tract infection","Urinary tract infection","Blood triglycerides increased"]}}